Welcome to our dedicated page for Azitra SEC filings (Ticker: AZTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Azitra, Inc. (AZTR) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, which are central to understanding this clinical stage biopharmaceutical issuer focused on precision dermatology. Through its Forms 8-K, S-1, DEF 14A and related documents, Azitra outlines the status of its live biotherapeutic and engineered protein programs, capital structure, and stock exchange compliance.
Filings such as Form 8-K detail material events, including notices from NYSE American regarding non-compliance with minimum stockholders’ equity requirements and subsequent acceptance of Azitra’s plan to regain compliance by April 1, 2027. Other 8-K reports describe private placement transactions involving common stock, pre-funded warrants, and common stock purchase warrants, as well as placement agency agreements and registration rights agreements tied to these financings. Additional 8-Ks furnish quarterly financial results and discuss reverse stock split actions implemented through amendments to the company’s certificate of incorporation.
Azitra’s Form S-1 registration statements provide further insight into its equity line of credit with Alumni Capital LP, the potential issuance of ELOC shares and warrants, and the resale registration of securities issued in private transactions. These documents explain how the company may raise capital over time and the number and types of securities that may be issued. The DEF 14A definitive proxy statement for a Special Meeting of Stockholders describes proposals to approve share issuances under NYSE American rules, including shares underlying warrants issued pursuant to a securities purchase agreement.
On this page, Stock Titan pairs Azitra’s real-time EDGAR filings feed with AI-powered summaries that help explain the significance of key documents. Users can quickly understand stock issuance proposals, listing standard issues, reverse stock splits, and financing structures without reading every page of each filing. Access to forms related to insider or major holder transactions, when filed, complements this view by showing how ownership and capital structure evolve as Azitra advances its ATR-12, ATR-04, and ATR-01 programs.
Azitra, Inc. reported an equity award to its President, CEO and director, Francisco D. Salva. On 12/19/2025, he received a stock option to buy 59,309 shares of Azitra common stock at an exercise price of $0.2968 per share. The option expires on 12/19/2035.
According to the vesting terms, 25% of the shares vest on the grant date, with the remaining shares vesting in equal monthly installments over the next 36 months of continuous service. Following this grant, 59,309 derivative securities are beneficially owned directly.
Azitra, Inc. director Barbara Ryan reported receiving a new stock option grant. On 12/19/2025, she was awarded options to purchase 3,003 shares of Azitra common stock at an exercise price of $0.2968 per share. These options are held directly.
According to the vesting terms, 25% of the underlying shares vest on the grant date, referred to as the Vesting Commencement Date. The remaining shares vest in equal monthly installments over the following 36 months of continuous service. The options have an expiration date of 12/19/2035.
Azitra, Inc. reported an insider equity award for its Chief Financial Officer on a Form 4. On 12/19/2025, the CFO received stock options to buy 15,015 shares of Azitra common stock at an exercise price of $0.2968 per share. These options are exercisable through 12/19/2035.
According to the vesting terms, 25% of the shares underlying the option vest on the grant date, and the remaining balance vests in equal monthly installments over the next 36 months of continuous service. Following this transaction, the reporting person beneficially owns 15,015 derivative securities directly.
Azitra, Inc. director John R. Schroer reported receiving a stock option grant. On 12/19/2025, he was granted options to purchase 3,003 shares of Azitra common stock at an exercise price of $0.2968 per share, with no purchase price for the option itself.
According to the vesting terms, 25% of the shares underlying the option vest on the grant date, designated as the vesting commencement date. The remaining shares vest in equal monthly installments over the next 36 months of continuous service. The options are scheduled to expire on 12/19/2035, and following this grant Schroer beneficially owns 3,003 derivative securities directly.
Azitra, Inc. shareholder Alumni Capital LP and related entities filed an amended ownership report showing beneficial ownership of 1,132,622 Azitra common shares, or 9.99% of the class. The shares include stock already owned plus shares that may be acquired under an April 2025 purchase agreement and several series of warrants.
The filing explains 9.99% and 4.99% beneficial ownership limits embedded in the purchase agreement and warrants, which cap how many shares Alumni Capital and its affiliates can hold at any time. Alumni Capital currently owns 535,759 shares and has the right to acquire additional shares through commitment warrants, with potential increases if it sells some of its existing position.
The reporting persons state that the securities were not acquired and are not held for the purpose of changing or influencing control of Azitra.
Azitra, Inc. reports that NYSE American has accepted its plan to regain compliance with the exchange’s minimum stockholders’ equity listing standard and granted a plan period through April 1, 2027.
Azitra previously received a notice on October 1, 2025 that it was not in compliance with Section 1003(a)(ii), which requires stockholders’ equity of $4.0 million or more for companies that have reported losses from continuing operations or net losses in three of the four most recent fiscal years. During the plan period, the company must provide quarterly updates to NYSE American staff with its regular SEC reports, and the exchange may initiate delisting proceedings if Azitra fails to make sufficient progress or does not regain compliance by the deadline. Azitra cautions that there is no assurance it will meet the equity requirement or remain in compliance with other NYSE American listing standards.
Azitra, Inc. is registering up to 51,812,293 shares of common stock for resale by Alumni Capital and other selling stockholders under a November 2025 private placement and an existing equity line of credit (ELOC). The shares include stock already issued plus shares underlying pre-funded warrants, common stock purchase warrants, placement agent warrants and ELOC warrants. Azitra will not receive proceeds from stockholder resales but may receive up to about $1.57 million from cash exercise of November warrants and about $14.0 million from additional ELOC share sales, on top of $6.0 million previously raised, plus potential warrant exercise proceeds. Common stock outstanding was 10,740,697 shares as of December 15, 2025 and could rise to 62,552,990 shares if all related warrants are exercised. The company is an early-stage dermatology biotech with three lead engineered-microbe programs and faces significant financing needs, NYSE American equity deficiency issues and substantial dilution risk from these facilities.
Azitra, Inc. is registering 51,812,293 shares of common stock for resale by existing investors, tied mainly to a November 2025 private placement and an April 2025 equity line with Alumni Capital. The shares include stock already issued plus shares underlying November pre-funded warrants, common stock purchase warrants, placement agent warrants, and ELOC warrants. Azitra is not selling shares in this prospectus and will not receive proceeds from investors’ resales, though it may receive cash if the warrants are exercised and if additional ELOC Shares are sold under the purchase agreement. The company is an early-stage biopharmaceutical business developing engineered live biotherapeutics and proteins for precision dermatology, led by pipeline candidates ATR-12 for Netherton syndrome, ATR-04 for EGFR inhibitor–related rash, and ATR-01 for ichthyosis vulgaris. Azitra reports a going concern warning, working capital of about $0.4 million as of September 30, 2025, and a NYSE American notice for not meeting minimum stockholders’ equity requirements, and expects to need more capital to fund operations.
Azitra, Inc. entered into a private placement with a single institutional investor, raising approximately $1.5 million in gross proceeds through common stock and warrant issuances priced at a premium to market in line with NYSE rules. The company is selling 535,759 shares of common stock, pre-funded warrants for up to 4,151,741 shares at an exercise price of $0.0001 per share, and common warrants to purchase up to 4,687,500 shares at an exercise price of $0.32. The common warrants become exercisable upon shareholder approval and expire five years after that approval, while the pre-funded warrants are immediately exercisable and do not expire until fully exercised. Azitra will use the proceeds for general corporate purposes and agreed to customary lock-up, participation, and registration rights, including filing a resale registration statement within 20 days and seeking effectiveness within 60–90 days.
L1 Capital Global Opportunities Master Fund, Ltd. filed an amended Schedule 13G/A for Azitra, Inc. (AZTR), reporting beneficial ownership of 273,497 shares of Common Stock, representing 2.6% of the class.
The filing states that the 273,497 shares include Common Stock underlying 273,497 warrants. The percentage is based on 10,204,938 shares outstanding as of November 11, 2025, as referenced from the issuer’s Form 10-Q. The holder reports sole voting and dispositive power over 273,497 shares and certifies the securities were not acquired to change or influence control. The date of the event is November 14, 2025.